News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GlaxoSmithKline (GSK) Process Using Pall Rapid Microbiological Test Is First Approved By FDA


10/19/2005 5:11:32 PM

Pall Corporation (NYSE:PLL) announced today that the U.S. Food and Drug Administration (FDA) granted GlaxoSmithKline (GSK) approval to use the Pallchek(TM) Luminometer as part of the quality control process for its prescription nasal spray product in its Parma, Italy facility. The Pall rapid test enables GSK to release product to market up to four days earlier than before.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES